Search research articles
Contact Us
Filters
Showing results (301-310 of 627) with videos related to
Page
of 63
Sort By:
Journal of the American Heart Association
|
September 16, 2015
Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF)
Benjamin A Steinberg, Sunghee Kim, Laine Thomas, et al.
The American Journal of Medicine
|
April 12, 2017
Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites
Masaya Koshizaka, Renato D Lopes, L Kristin Newby, et al.
American Heart Journal
|
February 9, 2002
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial
Kenneth W Mahaffey, Matthew T Roe, Christopher K Dyke, et al.
Circulation
|
January 15, 2016
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
Michelle L O'Donoghue, Deepak L Bhatt, Gregg W Stone, et al.
Circulation
|
August 3, 2016
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
Matthew A Cavender, Deepak L Bhatt, Gregg W Stone, et al.
Circulation. Cardiovascular Quality and Outcomes
|
June 11, 2015
Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
James V Freeman, DaJuanicia N Simon, Alan S Go, et al.
Cardiovascular Research
|
April 7, 2021
Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial
Jie Yu, Jingwei Li, Phillip J Leaver, et al.
European Heart Journal
|
April 1, 2017
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial
Marco Valgimigli, Francesco Costa, Yuliya Lokhnygina, et al.
American Heart Journal
|
June 19, 2018
Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome
Taku Inohara, Karen Pieper, Daniel M Wojdyla, et al.
Circulation. Cardiovascular Interventions
|
August 13, 2017
Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX
Matthew A Cavender, Deepak L Bhatt, Gregg W Stone, et al.
Page
of 63
Search research articles
Search
Showing results (301-310 of 627) with videos related to
Sort By:
Page
of 63
Journal of the American Heart Association
|
September 16, 2015
Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF)
Benjamin A Steinberg, Sunghee Kim, Laine Thomas, et al.
The American Journal of Medicine
|
April 12, 2017
Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites
Masaya Koshizaka, Renato D Lopes, L Kristin Newby, et al.
American Heart Journal
|
February 9, 2002
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial
Kenneth W Mahaffey, Matthew T Roe, Christopher K Dyke, et al.
Circulation
|
January 15, 2016
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
Michelle L O'Donoghue, Deepak L Bhatt, Gregg W Stone, et al.
Circulation
|
August 3, 2016
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
Matthew A Cavender, Deepak L Bhatt, Gregg W Stone, et al.
Circulation. Cardiovascular Quality and Outcomes
|
June 11, 2015
Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
James V Freeman, DaJuanicia N Simon, Alan S Go, et al.
Cardiovascular Research
|
April 7, 2021
Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial
Jie Yu, Jingwei Li, Phillip J Leaver, et al.
European Heart Journal
|
April 1, 2017
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial
Marco Valgimigli, Francesco Costa, Yuliya Lokhnygina, et al.
American Heart Journal
|
June 19, 2018
Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome
Taku Inohara, Karen Pieper, Daniel M Wojdyla, et al.
Circulation. Cardiovascular Interventions
|
August 13, 2017
Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX
Matthew A Cavender, Deepak L Bhatt, Gregg W Stone, et al.
Page
of 63